An Open-label, Phase 1, Sequential Cohort, Single-Dose Escalation Study to Assess the Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Tecarfarin (Primary)
- Indications Thromboembolism; Thrombosis
- Focus Adverse reactions
- Sponsors Lee's Pharmaceutical
- 20 Nov 2019 Status changed from active, no longer recruiting to completed.
- 23 Sep 2019 Planned End Date changed from 1 Dec 2018 to 1 Oct 2019.
- 23 Sep 2019 Status changed from recruiting to active, no longer recruiting.